Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

This clinical trial is designed to assess the efficacy and safety of trastuzumab
deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based
chemotherapy in combination with pembrolizumab in participants with no prior therapy for
locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have
HER2-overexpressing and PD-L1 TPS <50% without known AGA that have locally available
therapies targeting their AGAs in first-line advanced/metastatic setting.

Treatment Sites in Georgia